U.S. Rare Disease Biotech Generates Billions in Revenue, CEO Sells Shares Worth Hundreds of Millions

Neil Kumar, CEO of U.S.-based rare‐disease biotech BridgeBio Pharma, Inc. (NASDAQ: BBIO), sold 80,000 shares of company common stock on April 9–10 and again on May 7–8 under a prearranged family‐trust trading plan, raising approximately $11 million (around KRW 15 billion) in each transaction. Even after these sales, he and his family trust retain roughly 5 million shares, maintaining significant exposure to the company’s equity.

In its Q1 2026 financial results filed May 7, BridgeBio Pharma reported revenues of $194.5 million (about KRW 270 billion), driven by strong sales of its ATTR‐CM therapies Atruvia and Beyontra. Expanded commercial and R&D investments led to a net loss of $164 million (approximately KRW 230 billion). The company also disclosed that Beyontra won ATTR‐CM approval in Brazil, that it submitted a U.S. NDA for its rare‐muscle‐disease candidate BBP-418, that its board approved a $500 million (roughly KRW 700 billion) share‐repurchase program, and that it held $940.2 million (about KRW 1.3 trillion) in cash and cash equivalents.

Following the Q1 revenue beat and pipeline progress, analysts have raised earnings forecasts and price targets—HC Wainwright lifted its target from $100 to $110. With BBP-418’s FDA submission now in, observers note it could become the first approved therapy for LGMD2I R9 patients, and discuss plans for small‐scale pediatric and other subtype trials.

BridgeBio Pharma, listed on Nasdaq, develops medicines for genetic diseases and genetically defined cancers. In addition to its marketed ATTR-CM therapies Atruvia and Beyontra, its late‐stage pipeline includes low‐dose infigratinib, encaleret, and BBP-418. Founder and CEO Neil Kumar has driven the company’s growth strategy since its IPO, retaining a substantial stake; the recent share sales were executed under a Rule 10b5-1 plan designed to diversify his holdings.